甲氨蝶呤药物浓度,Methotrexate concentration
1)Methotrexate concentration甲氨蝶呤药物浓度
2)methotrexate derivatives甲氨蝶呤衍生物
3)MTX complex甲氨蝶呤复合物
英文短句/例句
1.Preparation and Preliminary Cytology Investigation of Luteinizing Hormone-Releasing Hormone MethotrexateLH-RH-甲氨蝶呤复合物的制备及初步细胞学研究
2.PEGylated polyamidoamine dendrimer/methotrexate complex:pharmacokinetics and anti-tumor activity in normal and tumor-bearing rodentsPAMAM-PEG/甲氨蝶呤复合物在正常及荷瘤鼠体内的药动学和抗肿瘤活性
3.The Study of Sustained-Releasing Methotreate Combined Calcium Sulfate in the Treatment of Osteosarcoma;复合氨甲蝶呤硫酸钙人工骨缓释剂治疗骨肉瘤的实验研究
4.Random open control study of compound recipe Xiatianwu united with Methotrexate on rheumatoid arthritis复方夏天无联合甲氨蝶呤治疗类风湿关节炎的随机开放对照研究
5.One Case Report of MTX-Induced Aplastic Anemia and Literature Review甲氨蝶呤致再生障碍性贫血1例及文献复习
6.Nursing Care in the Treatment of Ectopic Pregnancy by Methotrexate plus Chinese Medicinal Herb甲氨蝶呤配合中药治疗异位妊娠的护理
7.The Clinical Study of Conservative Treating Ectopic Pregnancy with Traditional Chinese and Methotrexate Medicine中药联合甲氨蝶呤治疗异位妊娠的临床研究
8.The Analysis of 102 Cases Ectopic Pregnancy Patients Treated with Mifepristone United Methotrexate米非司酮联合甲氨蝶呤治疗异位妊娠分析102例
9.Injection of Diprospan with Methotrexate (MTX) in the treatment of infantile hemangioma得保松联合甲氨蝶呤注射治疗婴幼儿血管瘤
10.The Clinical Observation of Methotrexate Combined with Medicinal Herbs in the Treatment of Ectopic Pregnancy甲氨蝶呤联合中药治疗异位妊娠的临床观察
11.FDA approves methotrexate, an anti-metabolite derived from folic acid, and6- mercaptopurine as anti-cancer drugs.FDA批准叶酸衍化的抗代谢药甲氨蝶呤和6-巯基嘌呤作为抗癌药物.
12.Study on the Synthesis and Preliminary Target Tests of Conjugates of Methotrexate with Bisphosphonates as Bone-targeted Therapeutical Agents for Bone Tumors;骨靶向抗肿瘤药物：甲氨蝶呤-偕二膦酸偶联物的合成及初步靶向性研究
13.The Experimental Study of the Influence by MTX and Alkylating Agent upon SS Patients PBMC Cultivated in Vitro;甲氨蝶呤联合烷化剂对干燥综合征外周血单个核细胞作用的研究
14.Preclinical Study of New Anti-tumor Drug of Magnetic Albumin Microspheres Combining MTX;甲氨蝶呤磁性抗癌新药的临床前研究
15.Determination of Methotrexate in Human Serum by HPLCHPLC法测定人血清中甲氨蝶呤的浓度
16.Inhibition effects of methotrexate on CXCR3 mRNA expression in patient with psoriasis vulgaris甲氨蝶呤对银屑病CXCR3mRNA表达调控的研究
17.Experimental Study on Endosalpinx Damage Induced by Methotrexate甲氨蝶呤损伤大鼠输卵管的实验研究
18.The Process Monitoring of the Dissolution of Methopterin Tablets with Fiber-optic Medicine Dissolution Process Real Time Test System光纤药物溶出度实时测定仪监测甲氨蝶呤片的溶出度
相关短句/例句
methotrexate derivatives甲氨蝶呤衍生物
3)MTX complex甲氨蝶呤复合物
4)methotrexate[英][,meθ?"trekseit][美][,m?θ?"tr?kset]甲氨蝶呤
1.Preparation and the in vitro and in vivo release of PLGA microspheres containingmethotrexate for intra-articular injection;关节腔注射用甲氨蝶呤缓释微球的制备及体内外释药研究
2.Determination of the structural change ofmethotrexate as an implant under the high-temperature fusion by infrared spectroscopy;红外光谱法测试高温融熔工艺对甲氨蝶呤植入剂结构的影响
3.Flow Injection Chemiluminescence Determination of Methotrexate with On _ line Electrogenerated Hypochlorite;测定甲氨蝶呤的在线电生次氯酸根流动注射化学发光法
5)Methotrexate(MTX)甲氨蝶呤
1.Analysis of Correlation Factors on Methotrexate(MTX)Concentration in Children with Acute Lymphoblastic Leukemia大剂量甲氨蝶呤在急性淋巴细胞白血病患儿体内血药浓度的相关因素分析
2.OBJECTIVE To study the effects of methotrexate(MTX) and recombinant human tumor necrosis factor(rhTNF) to cultured chondrosarcoma cell lines.目的:研究甲氨蝶呤(MTX)及重组人肿瘤坏死因子(rhTNF)对体外培养软骨肉瘤细胞株的作用。
3.The potential of the PEGylated PAMAM dendrimer as an anti-tumor drug carrier was evaluated using methotrexate(MTX) as a model drug.通过包裹与释放实验研究该药物载体对抗癌药物甲氨蝶呤(MTX)的包裹及释放能力。
6)Methotrexate[英][,meθ?"trekseit][美][,m?θ?"tr?kset]氨甲蝶呤
1.Studies on the Electrochemical Behavior ofMethotrexate and Its Applicationat Co/GC Ion Implantation Modified Electrode;氨甲蝶呤在Co/GC离子注入修饰电极上电化学行为及其应用研究
2.The Treatment of Ectopic Pregnancy combiningMethotrexate and Mifepristone;氨甲蝶呤联合米非司酮治疗异位妊娠
3.Study on Pharmacokinetics and Pharmacodynamics of Single-dose Intramuscularly InjectedMethotrexate in the Treatment of Ectopic Pregnancy;单剂量肌肉注射氨甲蝶呤治疗异位妊娠的药动学及药效学研究
延伸阅读
甲氨蝶呤【通用名称】甲氨蝶呤【其他名称】甲氨蝶呤 甲氨蝶呤 拼音名：Jia’an Dieling 英文名：Methotrexate 书页号：2000年版二部－151 C20H22N8O5 454.45 本品的主要成分为Ｌ－（＋）－Ｎ－[4-[[(2，4-二氨基-6-蝶啶基)甲基]甲氨 基]苯甲酰基]谷氨酸。按干燥品计算，含C20H22N8O5不得少于90.0％。 【性状】 本品为橙黄色结晶性粉末。 本品在水、乙醇、氯仿或乙醚中几乎不溶；在稀碱溶液中易溶，在稀盐酸中溶解。 【鉴别】 (1) 取本品约5mg ，加0.5 ％碳酸铵溶液1ml 溶解后，加盐酸溶液(9→ 1000) 稀释成每1ml 中含10μg 的溶液，照分光度法（附录Ⅳ A）测定，在244nm与306nm 的波长处有最大吸收，在234nm与262nm 的波长处有最小吸收。 (2) 本品的红外光吸收图谱应与对照的图谱（光谱集108 图）一致。 【检查】 干燥失重 取本品，以五氧化二磷为干燥剂，在100 ℃减压干燥至恒重， 减失重量不得过12.0％（附录Ⅷ L）。 【含量测定】 照高效液相色谱法（附录Ⅴ D）测定。 色谱条件与系统适用性试验 用十八烷基硅烷键合硅胶为填充剂；以乙腈-7.0％枸橼 酸溶液-2.0％无水磷酸氢二钠溶液(10:10:80)为流动相；检测波长为302nm 。理论板数 按甲氨蝶呤计算应不低于1000，与叶酸峰的分离度应不小于8.0 。 测定法 取本品适量，精密称定，加流动相溶解并定量稀释制成每1ml 中约含0.1 mg的溶液，取10μl 注入液相色谱仪，量取峰面积；另取曾测定干燥失重的甲氨 蝶呤对照品，同法测定，按外标法以峰面积计算，即得。 【类别】 抗肿瘤药。 【贮藏】 遮光，密封，在阴凉处保存。 【制剂】 (1) 甲氨蝶呤片 (2) 注射用甲氨蝶呤
